FDA Approves Osimertinib for Advanced EGFR-Mutated NSCLC …
WEBSep 26, 2024 — On Sept. 25, the U.S. Food and Drug Administration approved osimertinib (Tagrisso) for adults with locally advanced, unresectable stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression during or after platinum-based chemoradiation therapy and whose tumors contain EGFR exon …
Tagrisso Approved for Unresectable, Stage III,
WEB5 days ago — The median progression-free survival was significantly longer in the osimertinib arm than in the placebo arm — 39.1 months and 5.6 months, respectively (hazard ratio, 0.16; 95% CI, 0.10-0.24; P ...
FDA Approves Osimertinib for Unresectable NSCLC - Medscape
WEB5 days ago — September 27, 2024. 0. The US Food and Drug Administration (FDA) has approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for the treatment of locally advanced, unresectable non–small ...
LAURA: Osimertinib Significantly Improves PFS in ... - ASCO Daily News
WEBJun 2, 2024 — EGFR TKI osimertinib demonstrated significantly improved PFS over placebo (39.1 vs 5.6 months) in a phase 3 trial of patients with unresectable stage III EGFR -mutant NSCLC following chemoradiotherapy (LBA4).
Osimertinib Improves Survival in Lung Cancer - NCI
WEBJul 5, 2023 — Osimertinib, which is taken daily as a pill, specifically targets and kills lung cancer cells with these genetic mutations. In the nearly 700-patient study, people who were randomly assigned to receive osimertinib after surgery to remove their tumor(s)—known as adjuvant therapy — lived substantially longer overall than people assigned to ...
FDA Approves Osimertinib With Chemotherapy for - ASCO Post
WEBFeb 19, 2024 — On February 16, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) with platinum-based chemotherapy for patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. FLAURA2.
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
WEBJun 4, 2023 — Osimertinib was approved as adjuvant treatment for resected, EGFR-mutated, stage IB to IIIA NSCLC 23-25 on the basis of a significant disease-free survival benefit over placebo in the primary ...
FDA approves osimertinib with chemotherapy for EGFR-mutated …
WEBOn February 16, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) with platinum-based chemotherapy for patients with locally advanced or...
Osimertinib with or without Chemotherapy in
WEBNov 8, 2023 — Osimertinib is a highly potent and selective EGFR-TKI, whereas therapy with pemetrexed and a platinum-based agent has a nonselective antitumor effect.
Osimertinib After Surgery Significantly Improves Survival in
WEBTreatment with osimertinib (Tagrisso®) after surgery significantly lowered the risk of death in adults with completely resected EGFR-mutated (EGFRm) stage IB, II, or IIIA non-small cell lung cancer (NSCLC), according to the findings of an international study.